Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Angiogenesis/Protein Tyrosine Kinase

Chemical Structure Cat. No. Product Name CAS No.
Aflibercept Chemical Structure
BCP27879 Aflibercept 862111-32-8
Aflibercept is a recombinant fusion protein and acts as a VEGF inhibitor. Aflibercept is used for the treatment of wet macular degeneration and metastatic colorectal cancer.
Y15 tetrahydrochloride Chemical Structure
BCP27854 Y15 tetrahydrochloride 4506-66-5
Y15 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth.
TAK-788 Chemical Structure
BCP31045 TAK-788 AP32788
TAK-788 is a small, oral inhibitor of EGFR [epidermal growth factor receptor] and HER2 [human epidermal growth factor receptor 2].
pp60c-src Fragment 521-533 Chemical Structure
BCP27682 pp60c-src Fragment 521-533 149299-77-4
pp60 c-src (521-533) (phosphorylated) is a peptide corresponding to the pp60c-src carboxy terminal regulatory domain; phosphorylated at Tyr527. Binds to pp60c-src and pp60v-src at the SH2 domain, suppressing their tyrosine kinase activity and transforming potential.
SU5208 Chemical Structure
BCP29246 SU5208 62540-08-3
WHI-P 97 Chemical Structure
BCP29062 WHI-P 97 211555-05-4
WHI-P97 is a rationally designed potent inhibitor of JAK-3.
FF-10101 Chemical Structure
BCP23613 FF-10101 FF-10101
FF-10101 is a novel irreversible FLT3 inhibitor, shows excellent efficacy against AML cells with FLT3 mutations
Avitinib maleate Chemical Structure
BCP19161 Avitinib maleate 1822357-78-7
Avitinib maleate, the maleate salt form of avitinib, is a pyrrolopyrimidine-based, irreversible epidermal growth factor receptor (EGFR) mutant-selective inhibitor(IC50= 7.68 nM), with potential antineoplastic activity.
PT-2385 R-Enantiomer Chemical Structure
BCP30945 PT-2385 R-Enantiomer 1672666-67-9
PT-2385 is a small molecule inhibitor with oral activity that inhibits hypoxia inducible factor (HIF)-2alpha heterodimerization and its subsequent binding to DNA by binding to HIF-2alpha.
LOXO-292 Chemical Structure
BCP30970 LOXO-292 2222755-14-6
LOXO-292 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC50s of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .
123下一页末页共 658 条记录 1 / 66 页 
0086-13720134139